来源：Gangtise投研

　　艾迪康控股（09860.HK）2024年全年业绩发布会：2024年，艾迪康实现逆势增长，常规业务同比增长8.2%，新客户数量增长8.8%，其中公立医院客户增长13%，有效推动整体业务发展。全年毛利率达37.7%，经调整后净利润1.63亿，优于行业平均水平。特检业务增长18%，肿瘤检测增长47%，得益于专业招标团队和市场策略调整。尽管面临挑战，公司通过增加300个检测项目，强化特检团队，提升竞争力，为未来持续增长奠定基础。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：王若云

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.